Drug Trial Radar · NCT05410145
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
442
Planned (sponsor's estimate)
Start
Aug 3, 2022
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- D3 Bio (Wuxi) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.
Conditions
- KRAS P.G12C
Interventions
D3S-001Drug
Oral
PembrolizumabDrug
Intravenous
CisplatinDrug
Intravenous
CarboplatinDrug
Intravenous
PemetrexedDrug
Intravenous
CetuximabDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: From first dose until 30 days after the last dose (or specified in the protocol).
- Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: From Cycle 1 Day 1 through Day 21. Each cycle is 21 days.
Locations
52 sites in 10 countries. Site status is shown where the registry gives one.
D3 Bio Investigative Site 0402
Orange, California · Recruiting
D3 Bio Investigative Site 0407
Palo Alto, California · Recruiting
D3 Bio Investigative Site 0404
Denver, Colorado · Recruiting
D3 Bio Investigative Site 0406
Sarasota, Florida · Recruiting
D3 Bio Investigative Site 0401
Detroit, Michigan · Recruiting
D3 Bio Investigative Site 0405
Nashville, Tennessee · Recruiting
D3 Bio Investigative Site 0403
Houston, Texas · Recruiting
D3 Bio Investigative Site 0104
Bedford Park, Australia · Recruiting
D3 Bio Investigative Site 0102
Sydney, New South Wales, Australia · Recruiting
D3 Bio Investigative Site 0101
Malvern, Victoria, Australia · Recruiting
D3 Bio Investigative Site 0105
Melbourne, Victoria, Australia · Recruiting
D3 Bio Investigative Site 0103
Nedlands, Western Australia, Australia · Recruiting
D3 Bio Investigative Site 0314
Hefei, Anhui, China · Recruiting
D3 Bio Investigative Site 0303
Beijing, Beijing Municipality, China · Recruiting
D3 Bio Investigative Site 0306
Guangzhou, Guangdong, China · Recruiting
D3 Bio Investigative Site 0305
Hangzhou, Hangzhou, China · Recruiting
D3 Bio Investigative Site 0307
Harbin, Heilongjiang, China · Recruiting
D3 Bio Investigative Site 0309
Wuhan, Hubei, China · Recruiting
D3 Bio Investigative Site 0312
Wuhan, Hubei, China · Recruiting
D3 Bio Investigative Site 0315
Changsha, Hunan, China · Recruiting
D3 Bio Investigative Site 0313
Zhengzhou, Hunan, China · Recruiting
D3 Bio Investigative Site 0304
Nanchang, Jiangxi, China · Recruiting
D3 Bio Investigative Site 0302
Shenyang, Liaoning, China · Recruiting
D3 Bio Investigative Site 0310
Jinan, Shandong, China · Recruiting
D3 Bio Investigative Site 0301
Shanghai, Shanghai Municipality, China · Recruiting
D3 Bio Investigative Site 0308
Shanghai, Shanghai Municipality, China · Recruiting
D3 Bio Investigative Site 0316
Chengdu, Sichuan, China · Recruiting
D3 Bio Investigative Site 0311
Hangzhou, Zhejiang, China · Recruiting
D3 Bio Investigative Site 0804
Bordeaux, France · Recruiting
D3 Bio Investigative Site 0803
Lyon, France · Recruiting
D3 Bio Investigative Site 0801
Rennes, France · Recruiting
D3 Bio Investigative Site 0802
Villejuif, France · Recruiting
D3 Bio Investigative Site 1002
Hamburg, Germany · Recruiting
D3 Bio Investigative Site 1003
Cologne, North Rhine-Westphalia, Germany · Recruiting
D3 Bio Investigative Site 0501
Shatin, Hong Kong · Recruiting
D3 Bio Investigative Site 0905
Candiolo, Italy · Recruiting
D3 Bio Investigative Site 0902
Milan, Italy · Recruiting
D3 Bio Investigative Site 0904
Naples, Italy · Recruiting
D3 Bio Investigative Site 0901
Rome, Italy · Recruiting
D3 Bio Investigative Site 0903
Siena, Italy · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.